Wednesday, 04 February 2015 02:12 PM
BOCA RATON, FL / ACCESSWIRE / February 4, 2015 / LifeTech Capital, a research-focused biotechnology and medical technology investment bank has initiated research coverage on Cellular Biomedicine Group (NASDAQ: CBMG) with a Strong Speculative Buy rating and $23.75 price target.
The 25-page initiation report authored by Stephen M. Dunn, Senior Managing Director of Research at LifeTech Capital discusses Cellular Biomedicine Group's focus on the China healthcare market and their human clinical trials for ReJoin(TM), their stem cell candidate for knee osteoarthritis and cartilage defects as well as pre-clinical indications in Asthma and COPD. Also discussed is the company's recent acquisition of 3rd generation CAR T-cell and PD-1 cellular technology as they build an immuno-oncology pipeline in China. In the report, Mr. Dunn states "We believe this relatively unknown biotech is significantly undervalued as their clinical programs and aggressive acquisition strategy begins to unlock additional value during 2015 and beyond."
The full Initiation Report, including important disclosures, is available for download free of charge at the LifeTech Capital website http://lifetechcapital.com/ltc/?p=4437.
About LifeTech Capital
LifeTech Capital, a division of Aurora Capital LLC (Member FINRA/SIPC), is a multi-disciplinary team of investment professionals specializing in serving the unique needs of the Life Sciences industry and the investor community that serves it. Our institutional research team provides exceptional industry insight into the complex analysis of determining the future value of drugs, devices and the companies and management teams that develop them. LifeTech Capital's investment banking team is extremely knowledgeable in both the Life Sciences and Wall Street with expertise in developing appropriate funding strategies and structures as well as M&A partnering for our clients. Our capital markets team has relationships with Life Science institutional investors plus a broad base of accredited retail investors through both Aurora Capital and investor syndicates. For more information, please see www.LifeTechCapital.com.
SOURCE: Lifetech Capital